{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T17:06:02Z","timestamp":1786208762983,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Local Research and Development Council S\u00f6dra \u00c4lvsborg","award":["VGFOUSA-799931"],"award-info":[{"award-number":["VGFOUSA-799931"]}]},{"name":"The healthcare board, region v\u00e4stra g\u00f6taland","award":["VGFOUREG-477211"],"award-info":[{"award-number":["VGFOUREG-477211"]}]},{"name":"The healthcare board, v\u00e4stra g\u00f6taland","award":["VGFOUREG-659551"],"award-info":[{"award-number":["VGFOUREG-659551"]}]},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The pneumococcal conjugate vaccine PCV7 was introduced in Southwest Sweden in the child vaccination program in 2009, followed by PCV13 in 2010 and PCV10 in 2015. In this retrospective cohort study we assessed the pneumococcal serotype distribution in relation to predisposing factors, clinical manifestations and outcome during seven years after PCV introduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data from 1278 patients with 1304 episodes of invasive pneumococcal disease (IPD) between January 2009 and December 2015 in Region V\u00e4stra G\u00f6taland, Sweden, were retrospectively collected from medical records. Pneumococcal isolates were serotyped by gel diffusion and\/or Quellung reactions performed at the Public Health Agency in Sweden. Associations between serotypes and clinical characteristics were statistically evaluated by use of Fisher\u2019s exact test, Mann-Whitney U test and Logistic regression analysis, whereas IPD episodes caused by serotypes over time were analyzed by Mantel-Haenszel chi-square test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      With the exception of serotype 3, the prevalence of PCV13 serotypes decreased during the study period, from 76% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009157) of all IPD episodes in 2009 to 25% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200942) in 2015 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) while non-PCV13 serotypes increased, mainly among patients \u226565\u2009years and in patients with predisposing factors, including cardiovascular disease, pulmonary disease and malignancy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 for all). Patients with predisposing factors, including those with malignancy, immune deficiency or renal disease, were more likely to have IPD caused by a serotype not included in PCV13 rather than a vaccine-included serotype. Serotype 3 was associated with intensive care unit admissions while serotype 1 and 7F caused IPD among healthier and younger patients. PCV13 serotypes were associated with invasive pneumonia, and non-PCV13 serotypes were associated with bacteremia with unknown focus and with manifestations other than pneumonia or meningitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Non-PCV13 serotypes caused the majority of IPD cases in Southwest Sweden, especially in patients \u226565\u2009years and in patients with predisposing factors. Serotype 3, included in PCV13, was prevalent and often caused severe disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06430-y","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T05:03:05Z","timestamp":1628053385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in Southwest Sweden"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-2355","authenticated-orcid":false,"given":"Karin","family":"Bergman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor","family":"H\u00e4rnqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Backhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birger","family":"Trollfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats S.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Kolberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Ockborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Mellgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Skovbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"issue":"11","key":"6430_CR1","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","volume":"18","author":"GBDLRI Collaborators","year":"2018","unstructured":"Collaborators GBDLRI. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Infect Dis. 2018;18(11):1191\u2013210.","journal-title":"Lancet Infect Dis"},{"key":"6430_CR2","unstructured":"Rekommendationer om pneumokockvaccination till riskgrupper. https:\/\/www.folkhalsomyndigheten.se\/publicerat-material\/publikationsarkiv\/r\/rekommendationer-om-pneumokockvaccination-\/?pub=56914. Accessed 27 Sept 2020."},{"issue":"1","key":"6430_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1086\/648593","volume":"201","author":"T Pilishvili","year":"2010","unstructured":"Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32\u201341. https:\/\/doi.org\/10.1086\/648593.","journal-title":"J Infect Dis"},{"issue":"1","key":"6430_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12879-015-1147-x","volume":"15","author":"M Tin Tin Htar","year":"2015","unstructured":"Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15(1):419. https:\/\/doi.org\/10.1186\/s12879-015-1147-x.","journal-title":"BMC Infect Dis"},{"issue":"27","key":"6430_CR5","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1016\/j.vaccine.2014.03.065","volume":"32","author":"S Ben-Shimol","year":"2014","unstructured":"Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32(27):3452\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.065.","journal-title":"Vaccine"},{"issue":"3","key":"6430_CR6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/cid\/ciz221","volume":"70","author":"C Levy","year":"2020","unstructured":"Levy C, Varon E, Ouldali N, Bechet S, Bonacorsi S, Cohen R. Changes in invasive pneumococcal disease Spectrum after 13-valent pneumococcal conjugate vaccine implementation. Clin Infect Dis. 2020;70(3):446\u201354. https:\/\/doi.org\/10.1093\/cid\/ciz221.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6430_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/cid\/ciy872","volume":"69","author":"NK Vadlamudi","year":"2019","unstructured":"Vadlamudi NK, Chen A, Marra F. Impact of the 13-valent pneumococcal conjugate vaccine among adults: a systematic review and meta-analysis. Clin Infect Dis. 2019;69(1):34\u201349. https:\/\/doi.org\/10.1093\/cid\/ciy872.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"6430_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220453","volume":"14","author":"M van der Linden","year":"2019","unstructured":"van der Linden M, Imohl M, Perniciaro S. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLoS One. 2019;14(8):e0220453. https:\/\/doi.org\/10.1371\/journal.pone.0220453.","journal-title":"PLoS One"},{"issue":"5","key":"6430_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/thoraxjnl-2018-211767","volume":"74","author":"G Hanquet","year":"2019","unstructured":"Hanquet G, Krizova P, Valentiner-Branth P, Ladhani SN, Nuorti JP, Lepoutre A, et al. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax. 2019;74(5):473\u201382. https:\/\/doi.org\/10.1136\/thoraxjnl-2018-211767.","journal-title":"Thorax"},{"issue":"9807","key":"6430_CR10","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","volume":"378","author":"DM Weinberger","year":"2011","unstructured":"Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378(9807):1962\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(10)62225-8.","journal-title":"Lancet"},{"issue":"4","key":"6430_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/00365548.2012.734919","volume":"45","author":"S Skovbjerg","year":"2013","unstructured":"Skovbjerg S, Soderstrom A, Hynsjo L, Normark BH, Ekdahl K, Ahren C. Low rate of pneumococci non-susceptible to penicillin in healthy Swedish toddlers. Scand J Infect Dis. 2013;45(4):279\u201384. https:\/\/doi.org\/10.3109\/00365548.2012.734919.","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"6430_CR12","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1183\/13993003.01451-2015","volume":"47","author":"I Galanis","year":"2016","unstructured":"Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjostrom K, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J. 2016;47(4):1208\u201318. https:\/\/doi.org\/10.1183\/13993003.01451-2015.","journal-title":"Eur Respir J"},{"issue":"1","key":"6430_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12879-016-1648-2","volume":"16","author":"E Backhaus","year":"2016","unstructured":"Backhaus E, Berg S, Andersson R, Ockborn G, Malmstrom P, Dahl M, et al. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis. 2016;16(1):367. https:\/\/doi.org\/10.1186\/s12879-016-1648-2.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"6430_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/clinids\/7.2.133","volume":"7","author":"LA Burman","year":"1985","unstructured":"Burman LA, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis. 1985;7(2):133\u201342. https:\/\/doi.org\/10.1093\/clinids\/7.2.133.","journal-title":"Rev Infect Dis"},{"issue":"6\u20137","key":"6430_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/00365540500532852","volume":"38","author":"S Berg","year":"2006","unstructured":"Berg S, Trollfors B, Persson E, Backhaus E, Larsson P, Ek E, et al. Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis. 2006;38(6\u20137):427\u201332. https:\/\/doi.org\/10.1080\/00365540500532852.","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"6430_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/00365548609032305","volume":"18","author":"LA Burman","year":"1986","unstructured":"Burman LA, Trollfors B, Norrby R, Falsen E, Haidl S, Henrichsen J. Serotype distribution of Streptococcus pneumoniae strains isolated from blood and cerebrospinal fluid in Sweden. Scand J Infect Dis. 1986;18(1):45\u20138. https:\/\/doi.org\/10.3109\/00365548609032305.","journal-title":"Scand J Infect Dis"},{"issue":"6","key":"6430_CR17","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1183\/09031936.00080814","volume":"44","author":"S Browall","year":"2014","unstructured":"Browall S, Backhaus E, Naucler P, Galanis I, Sjostrom K, Karlsson D, et al. Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types. Eur Respir J. 2014;44(6):1646\u201357. https:\/\/doi.org\/10.1183\/09031936.00080814.","journal-title":"Eur Respir J"},{"issue":"11","key":"6430_CR18","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/cid\/cix685","volume":"65","author":"P Naucler","year":"2017","unstructured":"Naucler P, Galanis I, Morfeldt E, Darenberg J, \u00d6rtqvist \u00c5, Henriques-Normark B. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations. Clin Infect Dis. 2017;65(11):1780\u20131790.e1781.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6430_CR19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/1471-2334-13-492","volume":"13","author":"J Ahl","year":"2013","unstructured":"Ahl J, Littorin N, Forsgren A, Odenholt I, Resman F, Riesbeck K. High incidence of septic shock caused by Streptococcus pneumoniae serotype 3--a retrospective epidemiological study. BMC Infect Dis. 2013;13(1):492. https:\/\/doi.org\/10.1186\/1471-2334-13-492.","journal-title":"BMC Infect Dis"},{"issue":"34","key":"6430_CR20","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1016\/j.vaccine.2011.05.099","volume":"29","author":"MA Rodriguez","year":"2011","unstructured":"Rodriguez MA, Gonzalez AV, Gavin MA, Martinez FM, Marin NG, Blazquez BR, et al. Invasive pneumococcal disease: association between serotype, clinical presentation and lethality. Vaccine. 2011;29(34):5740\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2011.05.099.","journal-title":"Vaccine"},{"issue":"1","key":"6430_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/cid\/ciy875","volume":"69","author":"DM Weinberger","year":"2019","unstructured":"Weinberger DM, Warren JL, Dalby T, Shapiro ED, Valentiner-Branth P, Slotved HC, et al. Differences in the impact of pneumococcal serotype replacement in individuals with and without underlying medical conditions. Clin Infect Dis. 2019;69(1):100\u20136. https:\/\/doi.org\/10.1093\/cid\/ciy875.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"6430_CR22","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1093\/cid\/ciaa043","volume":"71","author":"Z Amin-Chowdhury","year":"2020","unstructured":"Amin-Chowdhury Z, Collins S, Sheppard C, Litt D, Fry NK, Andrews N, et al. Characteristics of invasive pneumococcal disease (IPD) caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in England; prospective observational cohort study, 2014-18. Clin Infect Dis. 2020;71(8):e235\u201343. https:\/\/doi.org\/10.1093\/cid\/ciaa043.","journal-title":"Clin Infect Dis"},{"key":"6430_CR23","unstructured":"Statistika centralbyr\u00e5n. https:\/\/www.scb.se. Accessed 1 Apr 2017."},{"key":"6430_CR24","doi-asserted-by":"publisher","unstructured":"Dahl MS, Trollfors B, Claesson BA, Brandberg LL, Rosengren A. Invasive pneumococcal infections in southwestern Sweden: a second follow-up period of 15 years. Scand J Infect Dis. 2001;33(9):667\u201372. https:\/\/doi.org\/10.1080\/00365540110026818.","DOI":"10.1080\/00365540110026818"},{"issue":"12","key":"6430_CR25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3109\/23744235.2015.1078907","volume":"47","author":"M Brink","year":"2015","unstructured":"Brink M, Welinder-Olsson C, Hagberg L. Time window for positive cerebrospinal fluid broad-range bacterial PCR and Streptococcus pneumoniae immunochromatographic test in acute bacterial meningitis. Infect Dis (Lond). 2015;47(12):869\u201377. https:\/\/doi.org\/10.3109\/23744235.2015.1078907.","journal-title":"Infect Dis (Lond)"},{"issue":"6","key":"6430_CR26","first-page":"699","volume":"43","author":"R Austrian","year":"1976","unstructured":"Austrian R. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med. 1976;43(6):699\u2013709.","journal-title":"Mt Sinai J Med"},{"issue":"6","key":"6430_CR27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1086\/655828","volume":"51","author":"DM Weinberger","year":"2010","unstructured":"Weinberger DM, Harboe ZB, Sanders EA, Ndiritu M, Klugman KP, Ruckinger S, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis. 2010;51(6):692\u20139. https:\/\/doi.org\/10.1086\/655828.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"6430_CR28","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1017\/S0950268816000856","volume":"144","author":"GJ Hughes","year":"2016","unstructured":"Hughes GJ, Wright LB, Chapman KE, Wilson D, Gorton R. Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. Epidemiol Infect. 2016;144(12):2654\u201369. https:\/\/doi.org\/10.1017\/S0950268816000856.","journal-title":"Epidemiol Infect"},{"issue":"1","key":"6430_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11908-018-0607-z","volume":"20","author":"N Principi","year":"2018","unstructured":"Principi N, Di Cara G, Bizzarri I, Isidori C, Borgia P, Mignini C, et al. Prevention of invasive pneumococcal disease: problems emerged after some years of the 13-valent pneumococcal conjugate vaccine use. Curr Infect Dis Rep. 2018;20(1):1. https:\/\/doi.org\/10.1007\/s11908-018-0607-z.","journal-title":"Curr Infect Dis Rep"},{"issue":"12","key":"6430_CR30","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/cid\/ciy920","volume":"68","author":"H Sings","year":"2019","unstructured":"Sings H, Wals PD, Gessner B, Isturiz R, Laferri\u00cbre C, McLaughlin J, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies. Clin Infect Dis. 2019;68(12):2135\u201343. https:\/\/doi.org\/10.1093\/cid\/ciy920.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"6430_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1086\/649872","volume":"50","author":"ZB Harboe","year":"2010","unstructured":"Harboe ZB, Benfield TL, Valentiner-Branth P, Hjuler T, Lambertsen L, Kaltoft M, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis. 2010;50(3):329\u201337. https:\/\/doi.org\/10.1086\/649872.","journal-title":"Clin Infect Dis"},{"key":"6430_CR32","doi-asserted-by":"crossref","unstructured":"Ahmed SS, Pondo T, Xing W, McGee L, Farley M, Schaffner W, Thomas A, Reingold A, Harrison LH, Lynfield R, et al. Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States.\u00a0Clin Infect Dis. 2020;70(12):2484\u201392.","DOI":"10.1093\/cid\/ciz739"},{"issue":"7","key":"6430_CR33","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1086\/423820","volume":"190","author":"AB Brueggemann","year":"2004","unstructured":"Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis. 2004;190(7):1203\u201311. https:\/\/doi.org\/10.1086\/423820.","journal-title":"J Infect Dis"},{"issue":"2","key":"6430_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/00365540802579007","volume":"41","author":"B Trollfors","year":"2009","unstructured":"Trollfors B, Berg S, Backhaus E, Andersson R, Bossen Konradsen H. Invasive, paediatric, vaccine strains of Streptococcus pneumoniae: are there differences in clinical characteristics? Scand J Infect Dis. 2009;41(2):84\u20137. https:\/\/doi.org\/10.1080\/00365540802579007.","journal-title":"Scand J Infect Dis"},{"issue":"8","key":"6430_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137108","volume":"10","author":"D Fatykhova","year":"2015","unstructured":"Fatykhova D, Rabes A, Machnik C, Guruprasad K, Pache F, Berg J, et al. Serotype 1 and 8 pneumococci evade sensing by Inflammasomes in human lung tissue. PLoS One. 2015;10(8):e0137108. https:\/\/doi.org\/10.1371\/journal.pone.0137108.","journal-title":"PLoS One"},{"key":"6430_CR36","unstructured":"Invasiv pneumokockinfektion. 2020.\u00a0https:\/\/www.folkhalsomyndigheten.se\/folkhalsorapportering-statistik\/statistik-a-o\/sjukdomsstatistik\/pneumokockinfektion-invasiv\/. Accessed 3 July 2021."},{"issue":"46","key":"6430_CR37","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","volume":"68","author":"A Matanock","year":"2019","unstructured":"Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >\/=65 years: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069\u201375. https:\/\/doi.org\/10.15585\/mmwr.mm6846a5.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6430_CR38","doi-asserted-by":"publisher","unstructured":"Hurley D, Griffin C, Young M, Scott DA, Pride MW, Scully IL, et al. Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age. Clin Infect Dis. 2020.\u00a0https:\/\/doi.org\/10.1093\/cid\/ciaa1045.","DOI":"10.1093\/cid\/ciaa1045"},{"issue":"3","key":"6430_CR39","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/21645515.2018.1532250","volume":"15","author":"JT Peterson","year":"2019","unstructured":"Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults \u226565 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccine Immunother. 2019;15(3):540\u20138. https:\/\/doi.org\/10.1080\/21645515.2018.1532250.","journal-title":"Hum Vaccine Immunother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06430-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T05:07:31Z","timestamp":1628053651000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06430-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6430"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06430-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-108666\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,4]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study and collection of clinical data was approved by the Regional Ethics Committee of Gothenburg (no 123\u201315 and T351\u201316). The committee did not require informed consent, because the clinical data was collected retrospectively and we had no contact with the study objects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EB is a former member of the advisory boards for Pfizer and GSK. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"756"}}